Insmed is sponsoring a clinical trial in the UK of its bronchial drug Brensocatib as a potential COVID-19 treatment.
Designated urgent by the UK's National Institute for Health Research, the trial will include up to 300 patients at 10 sites.
Patients enrollment is expected to begin in May.